Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants. 

Articles

In case you missed it, this week we had news about Dermavant's FDA-accepted sNDA for tapinarof cream 1% for AD, Eli Lilly's resubmitted BLA for lebrikizumab for AD, Rosacea Awareness Month recaps, and more. 

The Weekly Roundup: April 29-May 3

This week’s collection of the latest dermatologic studies includes social determinants of health in HS, JNJ-77242113 for moderate to severe plaque psoriasis, sonidegib for locally advanced and metastatic BCC, and pembrolizumab in combination with chemoradiotherapy for locally advanced HNSCC. 

Journal Digest: May 3 

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Robert Den, MD, and Alpha Tau are seeking motivated investigators who may be interested in participating in the trial.

Alpha Tau to Conduct Trial of Alpha DaRT Technology In Patients With Recurrent Squamous Cell Carcinoma

Our May issue of Dermatology Times spotlights melanoma/skin cancer awareness and more.

Recognizing Melanoma and Skin Cancer Awareness Month

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

Anti-Aging

BPDCN

Hair & Scalp

Rosacea

Skin Cancer (Melanoma)

Skin Cancer (Non-Melanoma)

1rem

View

Topical Treatments in Focus: Patient Journeys in Vitiligo

Dr. Elizabeth Kiracofe discusses a case of unstable vitiligo addressing the impact of an outdoor lifestyle on treatment, the efficacy of topical ruxolitinib.

Case 2: Male, 35 Years Old 

Dr Elizabeth Kiracofe discusses a case of unstable vitiligo in a 35-year-old male, addressing the impact of an outdoor lifestyle on treatment, the efficacy of topical ruxolitinib, and its utility in difficult-to-repigment areas.

Videos

Experts in dermatology provide insights from case-based roundtable conversations, discussing the management of patients with vitiligo. They emphasize the complexities of inherent to the management of this condition, the available treatment options and the administrative challenges associated with prior authorizations.

Elizabeth Kiracofe, MD, FAAD presents a case of a 42-year-old woman with facial vitiligo, emphasizing the need for personalized treatment plans. She shares insights on patient follow-up, monitoring practices, and physician preferences in treatment modalities based on the vehicle.

Case 1: Female, 42 Years Old

Dr. Elizabeth Kiracofe discusses a case of unstable vitiligo in a 35-year-old male, addressing the impact of an outdoor lifestyle on treatment, the efficacy of topical ruxolitinib, and its utility in difficult-to-repigment areas.

Case Based Peer Perspectives

Case 2: Male, 35 Years Old

EP: 1.Case 1: Female, 42 Years Old

EP: 2.Case 2: Male, 35 Years Old